News

TOKYO (June 18, 2019) –, Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Amgen Astellas has received approval in Japan for a supplemental indication for the hypercholesterolemia drug Repatha ® SC...

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor- -Data Featured in Official Press Program and Presented in Late-Breaking Oral Session Today at 2019 ASCO Annual Meeting- TOKYO and BOTHELL, Wash., June 3, 2019 – Astellas Pharma Inc. (TSE: 4503, President and...

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy 1 - - XOSPATA is the only FDA-approved targeted treatment for adult patients with relapsed or refractory FLT3 mutation-positive Acute Myeloid Leukemia 1 - TOKYO – May 30, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D....